LABORATORY RESEARCH Telomerase Reactivation following Telomere Dysfunction Yields Murine Prostate Tumors with Bone Metastases To determine the role of telomere dysfunction and telomerase reactivation in generating pro-oncogenic genomic events and in carcinoma progression, an inducible telomerase reverse transcriptase allele was crossed onto a prostate cancer-prone mouse model null for Pten and p53 tumor suppressors. [Cell] Abstract | Press Release Adult Murine Prostate Basal and Luminal Cells Are Self-Sustained Lineages that Can Both Serve as Targets for Prostate Cancer Initiation Using a lineage-tracing approach, researchers show that adult rodent prostate basal and luminal cells are independently self-sustained in vivo. [Cancer Cell] Abstract Pten Loss and RAS/MAPK Activation Cooperate to Promote Epithelial-to-Mesenchymal Transition and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells Researchers’ findings indicate that activation of RAS/MAPK signaling serves as a potentiating second hit to alteration of the PTEN/PI3K/AKT axis and co-targeting both pathways is highly effective in preventing the development of metastatic prostate cancers. [Cancer Res] Abstract Increased Expression of NuSAP in Recurrent Prostate Cancer Is Mediated by E2F1 To characterize the role and regulation of NuSAP in prostate cancer, researchers studied the expression of NuSAP in the LNCaP and PC3 human prostate cancer cell lines. [Oncogene] Abstract CCN3 Increases Cell Motility and ICAM-1 Expression in Prostate Cancer Cells Here, researchers show that nephroblastoma overexpressed (CCN3) increased cell migration and intercellular adhesion molecule-1 (ICAM-1) expression in prostate cancer cells. In addition, expression of CCN3 was positively correlated with both cell migration and ICAM-1 expression in human prostate cancer cells. [Carcinogenesis] Abstract miR-21 as an Independent Biochemical Recurrence Predictor and Potential Therapeutic Target for Prostate Cancer Researchers evaluated the microRNA miR-21 as a biomarker to predict the risk of biochemical failure, and as a potential drug target for prostate cancer therapy. [J Urol] Abstract Combining Growth Hormone-Releasing Hormone Antagonist with Luteinizing Hormone-Releasing Hormone Antagonist Greatly Augments Benign Prostatic Hyperplasia Shrinkage Researchers investigated the influence of a combination of antagonists of growth hormone-releasing hormone and luteinizing hormone-releasing hormone on animal models of benign prostatic hyperplasia. [J Urol] Abstract CLINICAL RESEARCH Improved Clinical Outcomes with High-Dose Image Guided Radiotherapy Compared with Non-IGRT for the Treatment of Clinically Localized Prostate Cancer The purpose of this study was to compare toxicity profiles and biochemical tumor control outcomes between patients treated with high-dose image-guided radiotherapy (IGRT) and high-dose intensity-modulated radiotherapy for clinically localized prostate cancer. [Int J Radiat Oncol Biol Phys] Abstract Survival among Men with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy or Radiation Therapy in the Prostate Specific Antigen Era Radical prostatectomy, external beam radiotherapy and brachytherapy are accepted treatments for localized prostate cancer. In this study, researchers analyzed the survival of patients treated with these modalities according to contemporary standards. [J Urol] Abstract The Results of Real-Time Brachytherapy for the Management of Low- and Intermediate-Risk Prostate Cancer in Patients with Prostate Volumes up to 100 mL The objective of this study was to report the results of real-time brachytherapy in the management of low-risk and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL, over a six-year period. [BJU Int] Abstract |